Señales en vivo de ATHE | Maximiza tus Ganancias con Getagraph.com

COMPRAR 112215 min ago

@ $1.920

Emitido: 14 feb 2024 @ 15:33

Retorno: 8.34%

Live Chart Being Loaded With Signals

Commentary (2 may 2024 @ 12:36):

Stats
Volumen de hoy	38 864.00
Volumen promedio	87 016.00
Capitalización de mercado	19.41M
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.020
ATR14	$0.0150 (0.72%)

Volumen Correlación

Largo: -0.17 (neutral)

Corto: 0.39 (neutral)

Signal:(43.351) Neutral

Alterity Therapeutics Correlación

10 Correlaciones Más Positivas
ZYXI	0.892
HAS	0.882
SNES	0.88
RUBY	0.876
PASG	0.875
SRTS	0.874
INTZ	0.872
SIGA	0.868
VNET	0.867
GETVV	0.867

10 Correlaciones Más Negativas
PLUS	-0.896
VCTR	-0.885
LOVE	-0.88
CRWD	-0.867
RDUS	-0.861
SHSP	-0.857
TVTY	-0.855
ZGNX	-0.852
TRNS	-0.847
PAE	-0.839

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Alterity Therapeutics Correlación - Moneda/Commodity

-0.40
( neutral )

-0.55
( weak negative )

0.10
( neutral )

-0.44
( neutral )

0.29
( neutral )

Alterity Therapeutics Finanzas

Annual	2023
Ingresos:	$2.61M
Beneficio Bruto:	$2.51M (96.08 %)
EPS:	$-0.00570

FY	2023
Ingresos:	$2.61M
Beneficio Bruto:	$2.51M (96.08 %)
EPS:	$-0.00570

FY	2022
Ingresos:	$3.54M
Beneficio Bruto:	$3.29M (92.88 %)
EPS:	$-0.00530

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.0541

Financial Reports:

No articles found.

Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.